Vericel Corporation - Common Stock (VCEL)

Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract. President and Chief Executive Offi

Vericel (VCEL) Q1 2026 Earnings Transcript

Vericel (VCEL) Q4 2025 Earnings Call Transcript

Vericel Corporation (NASDAQ: VCEL) stock rose on Tuesday after announcing preliminary financial results for 2025.

Vericel Corp. (VCEL) combines strong revenue growth and accelerating earnings with a technical setup suggesting a potential price breakout from a key support level.

Vericel Corp (VCEL) exemplifies GARP investing with strong growth, high profitability, and a valuation reasonable for its biotech sector.

Vericel (VCEL) offers affordable growth in biotech with strong revenue & earnings, solid financials, and a reasonable valuation relative to peers.

Brown Capital Discloses $31 Million Sale of Vericel Stock as Small-Cap Biotech Reports Earnings

Vericel (VCEL) Q3 2025 Earnings Call Transcript

Vericel (VCEL) beats Q3 2025 earnings estimates with strong revenue growth and a swing to profitability, driven by its MACI and burn care products.

Vericel (VCEL) combines strong revenue & earnings growth with a bullish technical setup, making it a top biotech growth stock to watch.

Vericel Corp (VCEL) is a high-growth biotech stock with strong fundamentals and a promising technical setup, making it a potential breakout candidate for investors.